Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299 oleh Arkadiusz Z. Dudek, MD, PhD, Min X. Xi, PhD, Katherine A. Scilla, MD, Hirva Mamdani, MD, Benjamin C. Creelan, MD, Andreas Saltos, MD, Tawee Tanvetyanon, MD, Alberto Chiappori, MD